Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma

Category	Detail
Condition	Newly diagnosed multiple myeloma (NDMM)
Key Mechanisms	Ixazomib is an oral proteasome inhibitor (PI) with once-weekly dosing, used as maintenance therapy post-primary treatment
Target Population	NDMM patients post-autologous stem cell transplantation (ASCT) or transplant-ineligible patients with at least partial response after induction therapy
Care Setting	Maintenance therapy setting following primary treatment for NDMM

Ixazomib maintenance therapy significantly improved progression-free survival (PFS) compared to placebo in both post-ASCT (MM3) and transplant-ineligible (MM4) NDMM patients.
Final overall survival (OS) analyses showed no statistically significant difference between ixazomib and placebo after extended follow-up in both studies.
The evolving treatment landscape with effective salvage therapies complicates OS as a primary endpoint in myeloma maintenance trials.

NDMM diagnosis with assessment of response post-primary therapy (ASCT or induction) to determine eligibility for maintenance therapy.

Ixazomib maintenance therapy administered orally on days 1, 8, and 15 of 28-day cycles for up to 24 months or until progression/toxicity.
Dose escalation from 3 mg to 4 mg after cycle 5 if tolerated.
Consider ixazomib as an alternative maintenance option especially in lenalidomide-exposed or refractory patients.

Regular assessment of disease progression and toxicity during maintenance therapy.
Monitoring health-related quality of life (HRQoL) using validated tools such as EORTC QLQ-C30.
Surveillance for new primary malignancies during maintenance.

Potential treatment burden with parenteral proteasome inhibitors avoided by oral ixazomib.
No significant OS benefit observed, highlighting need to balance PFS benefit with patient quality of life and subsequent therapies.

Patients with NDMM post-ASCT or transplant-ineligible patients achieving at least partial response after induction therapy.

Ixazomib maintenance improves PFS but does not significantly extend OS; well tolerated with oral administration and fixed-duration dosing.

Select patients with at least partial response following primary therapy for maintenance with ixazomib.
Use fixed-duration ixazomib maintenance (up to 24 months) with dose escalation based on tolerability.
Consider patient comorbidities, prior therapies, and treatment burden when choosing maintenance therapy.
Monitor closely for disease progression and adverse events to optimize treatment duration and quality of life.
Recognize that OS may be influenced by subsequent therapies; PFS remains a key endpoint for maintenance efficacy.

Clinical Scorecard: Final Overall Survival Results from the TOURMALINE-MM3 and -MM4 Randomized Controlled Trials Evaluating Ixazomib Maintenance Therapy in Newly Diagnosed Multiple Myeloma